Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Atorvastatin on Biomarkers of Acute Kidney Injury in Amikacin Recipients: A Pilot, Randomized, Placebo-Controlled, Clinical Trial Publisher



Heydari B1 ; Khalili H2 ; Beigmohammadi MT3 ; Abdollahi A4 ; Karimzadeh I5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  2. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Iran
  3. 3. Department of Anesthesiology and Intensive Care, Faculty of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pathology, Faculty of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

Source: Journal of Research in Medical Sciences Published:2017


Abstract

Background: The most common clinical indication of aminoglycosides (AG) is the treatment of serious Gram-negative infections. The aim of this study was to evaluate plausible effects of atorvastatin on the biomarkers of acute kidney injury (AKI) in patients receiving amikacin. Materials and Methods: In this double-blinded randomized clinical trial, fifty patients (25 in each group) receiving amikacin (15 mg/kg/day) were randomly assigned to either atorvastatin (40 mg/day) or placebo (40 mg/day) groups for 7 days. Blood urea nitrogen (BUN), serum creatinine (SCr), and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels were measured at days 0, 1, and 7 of amikacin treatment. Results: During the study period, 4 (8%) patients including two patients in each atorvastatin and placebo group experienced AKI. Urine NGAL/urine Cr did not change significantly between and within placebo and atorvastatin groups during the study period. Similarly, the mean changes in SCr, BUN, and urine NGAL/urine Cr values did not differ significantly between and within patients with and without AKI. Conclusion: Our data suggested that the changing pattern of urine NGAL/urine Cr ratio did not differ significantly between the atorvastatin and placebo groups during the early phase of amikacin treatment. © 2017 Journal of Research in Medical Sciences.
Related Docs
1. Evaluation of Urinary Neutrophil Gelatinase-Associated Lipocalin and Urinary Kidney Injury Molecule-1 As Biomarkers of Renal Function in Cancer Patients Treated With Cisplatin, Journal of Oncology Pharmacy Practice (2020)
2. Atorvastatin for Prevention of Amikacin-Induced Electrolytes Imbalances; a Randomized Clinical Trial, Iranian Journal of Pharmaceutical Research (2016)
3. The Effect of Melatonin on Cisplatin-Induced Nephrotoxicity: A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial, European Journal of Integrative Medicine (2020)
4. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report From a Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial, Phytotherapy Research (2015)
5. Urine Ratio of Neutrophil Gelatinase-Associated Lipocalin to Creatinine As a Marker for Early Detection of Cisplatinassociated Nephrotoxicity, Iranian Journal of Kidney Diseases (2015)
Experts (# of related papers)
View all Related Experts
Simin Dashti-Khavidaki (3)
Farhad Shahi (2)